Log in

Editas Medicine News Headlines (NASDAQ:EDIT)

$22.86
+0.20 (+0.88 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$22.64
Now: $22.86
$23.30
50-Day Range
$19.36
MA: $21.14
$23.11
52-Week Range
$17.80
Now: $22.86
$32.46
Volume460,200 shs
Average Volume534,465 shs
Market Capitalization$1.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.47

Headlines

Editas Medicine (NASDAQ EDIT) News Headlines

Source:
DateHeadline
FY2019 Earnings Forecast for Editas Medicine Inc Issued By Oppenheimer (NASDAQ:EDIT)FY2019 Earnings Forecast for Editas Medicine Inc Issued By Oppenheimer (NASDAQ:EDIT)
www.americanbankingnews.com - November 15 at 11:53 AM
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene DealEditas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
finance.yahoo.com - November 13 at 10:40 AM
BRIEF-Editas Medicine And Celgene Corporation Amend Existing CollaborationBRIEF-Editas Medicine And Celgene Corporation Amend Existing Collaboration
www.msn.com - November 13 at 5:40 AM
Editas Medicine, Inc. (EDIT) Q3 2019 Earnings Call TranscriptEditas Medicine, Inc. (EDIT) Q3 2019 Earnings Call Transcript
www.fool.com - November 12 at 10:17 PM
Edited Transcript of EDIT earnings conference call or presentation 12-Nov-19 1:00pm GMTEdited Transcript of EDIT earnings conference call or presentation 12-Nov-19 1:00pm GMT
finance.yahoo.com - November 12 at 10:17 PM
Editas Medicine (NASDAQ:EDIT) Issues  Earnings Results, Beats Expectations By $0.07 EPSEditas Medicine (NASDAQ:EDIT) Issues Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - November 12 at 9:31 PM
Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q3 2019 Results Earnings Call - TranscriptEditas Medicine, Inc. (EDIT) CEO Cindy Collins on Q3 2019 Results Earnings Call - Transcript
seekingalpha.com - November 12 at 5:17 PM
Editas Medicine, Inc. 2019 Q3 - Results - Earnings Call PresentationEditas Medicine, Inc. 2019 Q3 - Results - Earnings Call Presentation
seekingalpha.com - November 12 at 12:16 PM
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue EstimatesEditas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 12 at 12:16 PM
Editas Medicine EPS beats by $0.06, misses on revenueEditas Medicine EPS beats by $0.06, misses on revenue
seekingalpha.com - November 12 at 7:15 AM
Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune DiseasesEditas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases
finance.yahoo.com - November 12 at 7:15 AM
Editas Medicine Announces Third Quarter 2019 Results and UpdateEditas Medicine Announces Third Quarter 2019 Results and Update
finance.yahoo.com - November 12 at 7:15 AM
Editas Medicine Q3 2019 Earnings PreviewEditas Medicine Q3 2019 Earnings Preview
seekingalpha.com - November 11 at 7:55 PM
Editas Medicine Inc (NASDAQ:EDIT) Given Average Recommendation of "Hold" by AnalystsEditas Medicine Inc (NASDAQ:EDIT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 9 at 1:34 AM
 Brokerages Expect Editas Medicine Inc (NASDAQ:EDIT) Will Announce Quarterly Sales of $4.11 Million Brokerages Expect Editas Medicine Inc (NASDAQ:EDIT) Will Announce Quarterly Sales of $4.11 Million
www.americanbankingnews.com - November 7 at 7:12 AM
Editas Medicine (EDIT) Scheduled to Post Earnings on TuesdayEditas Medicine (EDIT) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - November 6 at 10:35 AM
Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate UpdateEditas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update
finance.yahoo.com - November 5 at 12:53 PM
-$0.70 Earnings Per Share Expected for Editas Medicine Inc (NASDAQ:EDIT) This Quarter-$0.70 Earnings Per Share Expected for Editas Medicine Inc (NASDAQ:EDIT) This Quarter
www.americanbankingnews.com - November 5 at 5:35 AM
Editas Medicine Inc (NASDAQ:EDIT) Sees Large Drop in Short InterestEditas Medicine Inc (NASDAQ:EDIT) Sees Large Drop in Short Interest
www.americanbankingnews.com - November 2 at 8:57 PM
Editas Medicine In The Realm Of Designer HumansEditas Medicine In The Realm Of Designer Humans
seekingalpha.com - November 1 at 5:16 PM
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - October 30 at 1:02 PM
Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical OfficerEditas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer
finance.yahoo.com - October 28 at 7:37 PM
Is Editas Medicine, Inc. (EDIT) Going to Burn These Hedge Funds?Is Editas Medicine, Inc. (EDIT) Going to Burn These Hedge Funds?
finance.yahoo.com - October 28 at 2:37 PM
Moving Average Crossover Alert: Editas MedicineMoving Average Crossover Alert: Editas Medicine
finance.yahoo.com - October 23 at 3:00 PM
Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In GrowthCompanies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth
finance.yahoo.com - October 19 at 2:13 PM
Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological DiseasesEditas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
finance.yahoo.com - October 15 at 10:43 PM
BRIEF-Editas Medicine And Maxcyte Announce Clinical And Commercial License Deal For Engineered Cell MedicinesBRIEF-Editas Medicine And Maxcyte Announce Clinical And Commercial License Deal For Engineered Cell Medicines
www.msn.com - October 7 at 11:58 PM
Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell MedicinesEditas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines
finance.yahoo.com - October 7 at 8:56 AM
Adverum Reports Data From Phase I Wet AMD Study, Stock DownAdverum Reports Data From Phase I Wet AMD Study, Stock Down
finance.yahoo.com - September 13 at 1:18 PM
Why Is Editas (EDIT) Down 5.5% Since Last Earnings Report?Why Is Editas (EDIT) Down 5.5% Since Last Earnings Report?
finance.yahoo.com - September 6 at 9:58 AM
Need To Know: Editas Medicine, Inc. (NASDAQ:EDIT) Insiders Have Been Buying SharesNeed To Know: Editas Medicine, Inc. (NASDAQ:EDIT) Insiders Have Been Buying Shares
finance.yahoo.com - September 5 at 8:39 AM
EDIT Makes Notable Cross Below Critical Moving AverageEDIT Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - September 3 at 9:01 PM
Editas Medicine: A Good Proxy For The Gene Editing SpaceEditas Medicine: A Good Proxy For The Gene Editing Space
seekingalpha.com - September 3 at 9:01 PM
CRISPR gene-editing technique set to push new boundariesCRISPR gene-editing technique set to push new boundaries
finance.yahoo.com - August 27 at 8:04 AM
Edited Transcript of EDIT earnings conference call or presentation 6-Aug-19 9:00pm GMTEdited Transcript of EDIT earnings conference call or presentation 6-Aug-19 9:00pm GMT
finance.yahoo.com - August 9 at 5:55 AM
Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEOEditas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
finance.yahoo.com - August 8 at 12:08 AM
Editas Medicine (EDIT) Reports Q2 Loss, Lags Revenue EstimatesEditas Medicine (EDIT) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 7 at 8:14 AM
New chief at EditasNew chief at Editas
seekingalpha.com - August 7 at 12:33 AM
Editas Medicine Announces Second Quarter 2019 Results and UpdateEditas Medicine Announces Second Quarter 2019 Results and Update
www.nasdaq.com - August 7 at 12:33 AM
BRIEF-Editas Medicine Reports Q2 Loss Per Share $0.69BRIEF-Editas Medicine Reports Q2 Loss Per Share $0.69
www.msn.com - August 7 at 12:33 AM
Editas picks Cindy Collins as permanent CEOEditas picks Cindy Collins as permanent CEO
www.bizjournals.com - August 7 at 12:33 AM
Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q2 2019 Results - Earnings Call TranscriptEditas Medicine, Inc. (EDIT) CEO Cindy Collins on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 12:33 AM
Editas Medicine Appoints Cynthia Collins as President and Chief Executive OfficerEditas Medicine Appoints Cynthia Collins as President and Chief Executive Officer
www.bloomberg.com - August 7 at 12:33 AM
Editas Medicine Q2 2019 Earnings PreviewEditas Medicine Q2 2019 Earnings Preview
seekingalpha.com - August 6 at 12:22 AM
2019 Gene Therapies Market Insights Updated Report By Leading Players Editas Medicine,Intellia Therapeutics,Homology Medicines and more2019 Gene Therapies Market Insights Updated Report By Leading Players Editas Medicine,Intellia Therapeutics,Homology Medicines and more
www.marketwatch.com - August 2 at 5:43 AM
Legal fight over Broad Institute's patent for CRISPR gene editing flares up againLegal fight over Broad Institute's patent for CRISPR gene editing flares up again
finance.yahoo.com - August 1 at 8:04 AM
Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate UpdateEditas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update
finance.yahoo.com - July 30 at 11:53 PM
Editas Medicine (EDIT) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseEditas Medicine (EDIT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - July 30 at 12:54 AM
BRIEF-Allergan And Editas Medicine Initiate The Brilliance Phase 1/2 Clinical Trial Of Agn-151587 For The Treatment Of Lca10BRIEF-Allergan And Editas Medicine Initiate The Brilliance Phase 1/2 Clinical Trial Of Agn-151587 For The Treatment Of Lca10
www.msn.com - July 26 at 5:21 AM
Editas launches first in-human study of CRISPR gene therapy for rare eye disorderEditas launches first in-human study of CRISPR gene therapy for rare eye disorder
seekingalpha.com - July 26 at 5:21 AM
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel